OTC · Drug Manufacturers - Specialty & Generic

Radnostix, Inc. (INIS) Stock

$0.06 -8.17% OTC: INIS Healthcare

Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals.

Valuation

MetricValue
Price$0.06
Market Cap$30.42M
P/E Ratio0.00
P/B Ratio11.48
P/S Ratio2.49
EPS (TTM)$0.00
52-Week High$0.11
52-Week Low$0.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-25.00%
ROA-5.56%
ROCE-17.28%
Gross Margin45.24%
Operating Margin-18.03%
Net Margin-7.69%
Debt/Equity3.32
Current Ratio0.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$11.0M$12.0M$14.0M$13.0M
Operating Profit$0$1.0M$-1.0M$0$-1.0M
Net Profit$-2.0M$0$-1.0M$0$-1.0M
EPS$0.00$0.00$0.00$0.00$0.00
Op Margin0.0%8.2%-6.3%0.1%-7.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$16.0M$17.0M$17.0M$18.0M
Total Liabilities$14.0M$12.0M$13.0M$13.0M$14.0M
Cash$0$2.0M$3.0M$2.0M$1.70T
Borrowings$4.0M$4.0M$8.0M$8.0M$4.84T

Latest News

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio PR Newswire · Jul 2, 2026 Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown PR Newswire · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$1.0M$1.0M$1.0M
Investing Cash Flow$0$8.0M$0$-1.0M$-1.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$2.0M$0$0$0
Free Cash Flow$0$-2.0M$0$0$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-26.82
FCF Yield-0.19%
Quick Ratio0.69
Interest Coverage-6.47
Return 1Y-47.73%
Return 3Y-28.12%
Return 5Y

Ownership

Insiders Held73.47%
Institutions Held0.00%
Institutions Float Held0.01%
Institutional HolderSharesReport Date
Capital Square, LLC20,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DBCCFDecibel Cannabis Company Inc. $0.08 -0.08% -20.00 $44.71M 0.00%
DXBRFBellRock Brands Inc. $0.00 0.00 $53153 0.00%
ETSTEarth Science Tech, Inc. $0.15 +7.14% 12.20 $43.23M 0.00%
FLOOFFlower One Holdings Inc. $0.00 -0.03 $4731 0.00%
MEDXFMedexus Pharmaceuticals Inc. $3.55 -1.61% -46.18 $112.46M 0.00%

About Radnostix, Inc.

Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.

Radnostix, Inc. is headquartered in US.

Radnostix, Inc. (INIS) stock trades at $0.06 with a market capitalization of $30.42M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 11.48, price-to-sales of 2.49. Over the past 52 weeks the stock has ranged between $0.05 and $0.11, and currently trades 45.5% below its 52-week high.

On profitability, Radnostix, Inc. generates a return on equity (ROE) of -25.00%, return on capital employed of -17.28%, an operating margin of -18.03%, a net profit margin of -7.69%.

Official website: radnostix.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides